These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8764084)

  • 1. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.
    Goudsmit J; De Ronde A; Ho DD; Perelson AS
    J Virol; 1996 Aug; 70(8):5662-4. PubMed ID: 8764084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.
    Goudsmit J; de Ronde A; de Rooij E; de Boer R
    J Virol; 1997 Jun; 71(6):4479-84. PubMed ID: 9151839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.
    Lu J; Whitcomb J; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):20-3. PubMed ID: 16123676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
    de Ronde A; van Dooren M; van Der Hoek L; Bouwhuis D; de Rooij E; van Gemen B; de Boer R; Goudsmit J
    J Virol; 2001 Jan; 75(2):595-602. PubMed ID: 11134272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
    Yerly S; Rakik A; De Loes SK; Hirschel B; Descamps D; Brun-Vézinet F; Perrin L
    J Virol; 1998 May; 72(5):3520-3. PubMed ID: 9557630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
    Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
    AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.
    Stilianakis NI; Boucher CA; De Jong MD; Van Leeuwen R; Schuurman R; De Boer RJ
    J Virol; 1997 Jan; 71(1):161-8. PubMed ID: 8985335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
    Harrigan PR; Bloor S; Larder BA
    J Virol; 1998 May; 72(5):3773-8. PubMed ID: 9557659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.
    Torti C; Gilleece Y; Hertogs K; Gazzard BG; Pozniak AL
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):514-5. PubMed ID: 11391177
    [No Abstract]   [Full Text] [Related]  

  • 16. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
    Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
    J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
    Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
    J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of zidovudine resistant strains of HIV-1: the first wave.
    Blower S
    AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
    [No Abstract]   [Full Text] [Related]  

  • 20. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.